Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5573823 | 1.00 | ELANE (0.40) | ELANEMAP4K4TRPM5HTR2AHTR2C | |
| SCHEMBL5629675 | 0.90 | DYRK3 (0.34) | ELANETRPM5MEN1KMT2AALDH1A1 | |
| SCHEMBL5574027 | 0.90 | DYRK3 (0.34) | ELANETRPM5MEN1KMT2AALDH1A1 | |
| SCHEMBL5571296 | 0.88 | ALDH1A1 (0.36) | MAP4K4HTR2AHTR2CHTR2BLMNA | |
| SCHEMBL5573841 | 0.88 | ALDH1A1 (0.36) | MAP4K4HTR2AHTR2CHTR2BLMNA | |
| SCHEMBL5574640 | 0.88 | KDM4E (0.39) | HTR2AHTR2CHTR2BLMNAHIF1A | |
| SCHEMBL5573751 | 0.86 | APP (0.36) | LMNAMEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL5573752 | 0.86 | APP (0.36) | LMNAMEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL5571285 | 0.86 | GSK3B (0.38) | MAP4K4HCRTR2LMNAABL1SRC | |
| SCHEMBL5571288 | 0.86 | GSK3B (0.38) | MAP4K4HCRTR2LMNAABL1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805174-A1 | 1,5-NAPHTHYRIDINE AZOLIDINONES HAVING CDK1 ANTIPROLIFERATIVE ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2007-07-11 | — | — | EP | claimed |
| WO-2006040052-A1 | 1,5-NAPHTHYRIDINE AZOLIDINONES HAVING CDK1 ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | WO | claimed |
| US-20060084673-A1 | 1,5-naphthyridine azolinone | LIU JIN-JUN | 2006-04-20 | — | — | US | claimed |
| US-7268231-B2 | 1,5-Naphthyridine azolinone | HOFFMANN-LA ROCHE INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1805174-A1 | 1,5-NAPHTHYRIDINE AZOLIDINONES HAVING CDK1 ANTIPROLIFERATIVE ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006040052-A1 | 1,5-NAPHTHYRIDINE AZOLIDINONES HAVING CDK1 ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | WO | disclosed |
| US-20060084673-A1 | 1,5-naphthyridine azolinone | LIU JIN-JUN | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084673-A1 | 1,5-naphthyridine azolinone | CDK1, CDK15, CDK14 | ELANE 3163/4885MAP4K4 162/4885TRPM5 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.